Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in the cell line development, process development, and small batch clinical production of antibodies, has announced the appointment of Dr. Roger Lias as President and Chief Operating Officer.
Lias most recently served as Chief Commercial Officer at Vibalogics, a viral vector CDMO that was acquired this year by Recipharm. In his capacity, Roger not only helped position Vibalogics for M&A success but was also integral in a major capital expansion project in the US. Roger brings a wealth of experience in the biologics CDMO arena, having held senior commercial roles at Lonza and Diosynth before becoming a member of the founding management teams at KBI Biopharma, Cytovance Biologics, and Eden Biodesign. More recently, Roger was the Chief Executive Officer at Avid Bioservices and Stelis Biopharma. At both companies he was responsible for the successful transition to dedicated CDMO models.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!